Nine of the largest pharma companies ink deals with Trump to lower drug prices

Impact · against what's priced in

The agreement to link U.S. drug prices to international 'most favored nation' levels and provide blockbusters like Eliquis for free creates immediate downward pressure on margins. While tariff exemptions provide a partial hedge, the structural erosion of pricing power for high-volume medications is a significant net negative for the participating pharmaceutical companies.

BMY−0.60

No priced-in read yet